SCHEMBL24310780

SCHEMBL24310780

Cn1cc(SNc2nc(OCCC(C)(C)O)cc(OCCC(C)(C)O)n2)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACVR2A P27037 2/20 0.36
▸ TGFBR2 P37173 2/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ IRAK1 P51617 3/20 0.34
▸ IRAK4 Q9NWZ3 2/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ JAK3 P52333 1/20 0.33
▸ FGFR1 P11362 1/20 0.32
▸ FGFR2 P21802 1/20 0.32
▸ FGFR4 P22455 1/20 0.32
▸ FGFR3 P22607 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ WNT1 P04628 1/20 0.31
▸ GSK3B P49841 1/20 0.31
▸ DYRK1A Q13627 1/20 0.31
▸ JAK1 P23458 1/20 0.31
▸ PIM1 P11309 1/20 0.31
▸ EGFR P00533 1/20 0.30
▸ TTK P33981 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24309478 0.87 IRAK1 (0.34) ACVR2ATGFBR2CYP2C9KCNH2IRAK1
SCHEMBL24309990 0.83 CYP19A1 (0.36) ACVR2ATGFBR2CYP2C9KCNH2
SCHEMBL24310079 0.82 ACVR2A (0.37) ACVR2ATGFBR2CYP2C9KCNH2IRAK1
SCHEMBL24310778 0.76 HTR1A (0.40) ACVR2ATGFBR2CYP2C9KCNH2IRAK1
SCHEMBL24309799 0.76 CYP2C9 (0.32) ACVR2ATGFBR2CYP2C9KCNH2IRAK1
SCHEMBL24309972 0.71 PIK3CG (0.38) ACVR2ATGFBR2CYP2C9KCNH2JAK2
SCHEMBL24310222 0.68 KDM5B (0.30) —
SCHEMBL26811230 0.67 HTR1A (0.37) ACVR2ATGFBR2CYP2C9KCNH2JAK1
SCHEMBL24310706 0.67 ALDH1A1 (0.33) —
SCHEMBL26811264 0.67 PIK3CG (0.38) ACVR2ATGFBR2CYP2C9KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback